Managing early-stage breast cancer in your older patients

ONCOLOGY

Volumn 20, Issue 9, 2006, Pages 1003-1012

  Witherby, Sabrina M ^a   Muss, Hyman B ^a,b  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANASTROZOLE; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CREATININE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; HEMOGLOBIN; IBANDRONIC ACID; LETROZOLE; METHOTREXATE; MONOCLONAL ANTIBODY; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; AGING; ANEMIA; ARTHRALGIA; AXILLARY LYMPH NODE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN ISCHEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITION; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; DAILY LIFE ACTIVITY; DISEASE COURSE; DRUG COST; DRUG SUBSTITUTION; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FEBRILE NEUTROPENIA; FRACTURE; GERIATRIC PATIENT; HOT FLUSH; HUMAN; HYSTERECTOMY; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LIFE EXPECTANCY; LOW DRUG DOSE; LYMPH NODE DISSECTION; MASTECTOMY; MEDICAL DECISION MAKING; META ANALYSIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVIEW; SENTINEL LYMPH NODE; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VEIN EMBOLISM; ADJUVANT CHEMOTHERAPY; AGED; BREAST TUMOR; FEMALE; MULTIMODALITY CANCER THERAPY; SEGMENTAL MASTECTOMY;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; COMORBIDITY; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 34250644941     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics. CA Cancer J Clin 55:10-30, 2005.
2. US Cancer Statistics Working Group. United States Cancer Statistics: 1998-2002, Incidence and Mortality, Web-Based Report Version. Atlanta; Department of Health and Human Services, Centers for Disease Control Prevention, and National Cancer Institute; 2005. Available at www.cdc.gov/cancer/npcr/uscs. Accessed July 11, 2006.
3. Public Health and Aging: United States and worldwide. JAMA 289:1371-1373, 2003.
4. Eppenberger-Castori S, Moore DH Jr, Thor AD, et al: Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 34:1318-1330, 2002.
5. Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92:550-556, 2000.
6. Basche M, Byers T: Re: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 93:64-65, 2001.
7. Weiss NS: Re: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 93:65-66, 2001.
8. Singh R, Hellman S, Heimann R: The natural history of breast carcinoma in the elderly: Implications for screening and treatment. Cancer 100:1807-1813, 2004.
9. Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104-110. 1994.
10. Yancik R, Wesley MN, Ries LA, et al: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885-892, 2001.
11. Carey EC, Walter LC, Lindquist K, et al: Development and validation of a functional morbidity index to predict mortality in community-dwelling elders. J Gen Intern Med 19:1027-1033, 2004.
12. Extermann M, Overcash J, Lyman GH, et al: Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16:1582-1587, 1998.
13. Extermann M, Aapro M, Bernabei R, et al: Use of comprehensive geriatric assessment in older cancer patients: Recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55:241-252, 2005.
14. Extermann M, Meyer J, McGinnis M, et al: A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 49:69-75, 2004.
15. Extermann M: Measurement and impact of comorbidity in older cancer patients. Hem Onc Clin North Am 35:181-200, 2000.
16. Wanebo HJ, Cole B, Chung M, et al: Is surgical management compromised in elderly patients with breast cancer? Ann Surg 225:579-586, 1997.
17. Singletary SE, Shallenberger R, Guinee VF: Breast cancer in the elderly. Ann Surg 218:667-671, 1993.
18. Veronesi U, Cascinelli N, Mariani L, et al: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 349:546-553, 2003.
19. Fisher B, Anderson S, Bryant J, et al: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233-1241, 2002.
20. Cutuli B, Aristei C, Martin C, et al: Breast conserving therapy for stage I-II breast cancer in elderly women. Int J Radiat Oncol Biol Phys 60:71-76, 2004.
21. Grube BJ, Hansen NM, Wei Y, et al: Surgical management of breast cancer in the elderly patients. Am J Surg 182:359-364, 2001.
22. de Haes JCJM, Curran D, Aaronson NK, et al: Quality of life in breast cancer patients aged over 70 years, participating in the EORTC 10850 randomised clinical trial. Eur J Cancer 39:945-951, 2003.
23. O'Connell JB, Maggard MA, Ko CY: Cancer-directed surgery for localized disease: decreased use in the elderly. Ann Surg Oncol 11:962-969, 2004.
24. Morrow W, White J, Moughan J, et al: Factors predicting the use of breast conserving therapy in stage I and II breast carcinoma. J Clin Oncol 19:2254-2264, 2001.
25. Audisio RA, Bozzetti F, Gennari R, et al: The surgical management of elderly cancer patients: Recommendations of the SIOG task force. Eur J Cancer 40:926-938, 2004.
26. Mandelblatt JS, Kerner JF, Hadley J, et al: Variations in breast carcinoma treatment in older medicare beneficiaries: Is it black or white? Cancer 95:1401-1414, 2002.
27. Martelli G, Miceli R, De Palo G, et al: Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axailla. Cancer 97:1156-1163, 2003.
28. Gennari R, Rotmensz N, Perego E, et al: Sentinel node biopsy in elderly breast cancer patients. Surg Oncol 13:193-196, 2004.
29. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174, 2003.
30. Eiermann W, Paepke S, Appfelstaedt J, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12:1527-1532, 2001.
31. Deutsch M: Radiotherapy after lumpectomy in very old women. Am J Clin Oncol 25:48, 2002.
32. Vinh-Hung V, Verschaegen C: Breast-conserving surgery with or without radiotherapy: Pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst 96:115-121, 2004.
33. Fyles AW, McCready DR, Manchul LA, et al: Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 351:963-970, 2004.
34. Hughes KS, Schnaper LA, Berry D, et al: Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 351:971-977, 2004.
35. Truong PT, Lee J, Kader HA, et al: Locoregional recurrence risks in elderly breast cancer patients treated with mastectomy without adjuvant radiation therapy. Eur J Cancer 41:1267-1277, 2005.
36. Akhtar SS, Allan SG, Rodger A: A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail patients. Eur J Surg Oncol 17:30-35, 1991.
37. Fentiman IS, Christiaens MR, Paridaens R, et al: Treatment of operable breast cancer in the elderly: A randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer 39:309-316, 2003.
38. Robertson JF, Ellis IO, Elston CW, et al: Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer 28A:908-910, 1992.
39. Gazet JC, Ford HT, Coombes RC, et al: Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol 20:207-214, 1994.
40. Mustacchi G, Ceccherini R, Milani S, et al: Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: Long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 14:414-420, 2003.
41. Fennessy M, Bates T, MacRae K, et al: Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg 91:699-704, 2004.
42. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001.
43. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001.
44. Extermann M, Balducci L, Lyman GH, et al: What threshold for adjuvant chemotherapy in older breast cancer patients? J Clin Oncol 18:1709-1717, 2000.
45. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005.
46. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352:930-942, 1998.
47. Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271, 2005.
48. Baum M, Buzdar AU, Cuzick J, et al, for the ATAC Trialists Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002.
49. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005.
50. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004.
51. Jakesz R, Jonat W, Ganat M, et al: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462, 2005.
52. Hillner BE, Ingle JN, Chlebowski RT, et al: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057, 2003.
53. Desch CE, Hillner BE, Smith TJ, et al: Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol 11:777-782, 1993.
54. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al: Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol 18:1412-1422, 2000.
55. Fisher B, Jeong JH, Anderson S, et al: Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: Updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 96:1823-1831, 2004.
56. Fisher B, Jeong JH, Bryant J, et al: Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364:858-868, 2004.
57. Fargeot P, Bonneterre J, Roche H, et al: Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol 22:4622-4630, 2004.
58. Muss HB, Woolf S, Berry D, et al: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073-1081, 2005.
59. Lichtman SM, Skirvin JA: Pharmacology of antineoplastic agents in older cancer patients. Oncology (Williston Park) 14:1743-1755, 2000.
60. Shapiro CL, Recht A: Drug therapy: Side effects of adjuvant treatment of breast cancer. N Engl J Med 344:1997-2008, 2001.
61. Dees EC, O'Reilly S, Goodman SN, et al: A prospective, pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 18:521-529, 2000.
62. Gelman RS, Taylor SG: Cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends with doses based on creatinine clearance. J Clin Oncol 2:1406-1414, 1984.
63. Balducci L, Lyman GH, Ozer W: Patients aged > or = 70 are at high risk for neutropenic infection and should receive hematopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol 19:1583-1585, 2001.
64. National Comprehensive Cancer Network: Guidelines for supportive care: Myeloid growth factors, version 1.2006. Available at www.nccn.org. Accessed July 12, 2006.
65. Lyman GH, Kuderer N, Agboola O, et al: Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control 10:487-499, 2003.
66. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979.
67. Kimmick GG, Shelton BJ, Case LD, et al: Long-term follow up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast. Breast Cancer Res Treat 72:233-243 2002.
68. Doyle JJ, Neugut AI, Jacobson JJ, et al: Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study (abstract 6085). Breast Cancer Res Treat 94(suppl 1):S278, 2005.
69. Hurria A, Rosen C, Zuckerman E, et al: Effect of adjuvant chemotherapy (CRx) on the cognitive function of older patients (pts) with breast cancer (BC): Results from a prospective study (abstract 8204). Proc Am Soc Clin Oncol 23(16S):779s, 2005.
70. Du XL, Osborne C, Goodwin JS: Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 20:4636-4642, 2002.
71. Hurria A, Brogan K, Panageas KS, et al: Pattern of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 92:151-156, 2005.
72. De Maio E, Gravina A, Pacilio C, et al: Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: A single center experience. BMC Cancer 5:30, 2005.
73. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al: Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluoruracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol 18:1412-1422, 2000.
74. Colleoni M, Price KN, Castiglione-Gertsch M, et al: Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. International Breast Cancer Study Group. Lancet 354:130-131, 1999.
75. Yardley DA, Loesch DM, Greco FA, et al: Preliminary toxicity results from a phase III multi-centered trial comparing weekly docetaxel to CMF as adjuvant treatment for high risk breast cancer patients who are not candidates for anthracyclines. (abstract 1061). Breast Cancer Res Treat 88(suppl 1):S62, 2004.
76. Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005.
77. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005.
78. The HERA study team. Trastuzumab (H: Herceptin) following adjuvant chemotherapy (CT) significantly improves disease-free survival (DFS) in early breast cancer with HER2 overexpression: The HERA trial (abstract 11). Breast Cancer Res Treat 94(suppl 1):S9, 2005.
79. Hutchins LF, Unger JM, Crowley JJ, et al: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067, 1999.
80. Kemeny MM, Peterson BL, Kornblith AB, et al: Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21:2268-2275, 2003.
81. Lara PN Jr, Higdon R, Lim N, et al: Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment. J Clin Oncol 19:1728-1733, 2001.
82. Siminoff LA, Zhang A, Saunders Sturm CM, et al: Referral of breast cancer patients to medical oncologists after initial surgical management [see comments]. Med Care 38:696-704, 2000.
83. Kemeny M, Muss HB, Kornblith AB, et al: Barriers to participation of older women with breast cancer in clinical trials (abstract 2371). Proc Am Soc Clin Oncol 19:602a, 2000.
84. Kornblith AB, Kemeny M, Peterson BL, et al: Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 95:989-996, 2002.
85. Schairer C, Mink PJ, Carroll L, et al: Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96:1311-1321, 2004.